Concord Biotech Limited
Tata AIA Life Insurance raised its stake in Concord Biotech from 2.48% to 2.68%, purchasing 2,14,980 shares.
An R&D-driven biopharma company engaged in manufacturing fermentation-based active pharmaceutical ingredients for immunosuppressants and oncology applications. Established in 1984, the company specializes in complex fermentation technology and serves domestic and international pharmaceutical markets with differentiated API solutions. Its focus on bioprocess innovation and vertical integration in fermentation-based manufacturing distinguishes it within the competitive global pharmaceutical ingredients landscape.
Joint venture between Tata Sons and AIA Group. AUM crossed Rs 1.3 lakh crore in May 2025, growing 27% YoY, making it one of the fastest-growing equity-oriented insurers in India. CIO Harshad Patil has run the investment book since 2014. Flagship Multi Cap Fund delivered 31.4% CAGR over 5 years, among the strongest performance in the ULIP universe.